Background: MicroRNA-876-5p (miR-876) dysregulation contributes to the aggressiveness of various types of human cancer. This study was aimed at measuring miR-876 expression in breast cancer, determining the specific roles of miR-876 in the progression of breast cancer and understanding the corresponding molecular mechanisms. Materials and methods: miR-876 expression in breast cancer tissues and cell lines was quantified via RT-qPCR. The effect of miR-876 upregulation on the malignant phenotype of breast cancer cells was investigated using CCK-8 assays, flow cytometry, Transwell migration and invasion assays and tumor xenograft experiments. The mechanisms underlying the tumor-suppressive action of miR-876 in breast cancer cells were explored using bioinformatic analysis, luciferase reporter assays, RT-qPCR and Western blot analysis. Results: miR-876 was found to be underexpressed in breast cancer tissues and cell lines. Decreased miR-876 expression notably correlated with lymphatic invasion metastasis, TNM stage and differentiation grade. Overall survival was lower among patients with breast cancer and low miR-876 expression than in patients with high miR-876 expression. Restoration of miR-876 expression decreased breast cancer cell proliferation, migration and invasion in vitro and restricted tumor growth in vivo as well as increased cell apoptosis. Metadherin (MTDH) was identified as a novel target of miR-876 in breast cancer cells. Furthermore, long intergenic nonprotein-coding RNA 707 (LINC00707) acted as a molecular sponge for miR-876, thereby regulating MTDH expression in breast cancer. Finally, silencing miR-876 expression attenuated the influence of a LINC00707 knockdown on the malignancy of breast cancer cells. Conclusion: This study, thus, revealed the vital functions of the LINC00707-miR-876-MTDH pathway in breast cancer and provided attractive targets and markers for its treatment.
Introduction
Breast cancer, which is derived from mammary epithelial tissue, is one of the most prevalent human malignant tumors among women worldwide. 1 Morbidity and mortality among patients with breast cancer in China accounts for approximately 12.2% and 9.6% of global figures, respectively. [2] [3] [4] In the past few decades, considerable advances in the diagnosis and treatment have led to an obvious improvement in the clinical outcomes of patients with breast cancer. Unfortunately, to date, breast cancer is still a refractory disease, mainly owing to its recurrence, metastasis and tolerance to radiotherapy and chemotherapy. [5] [6] [7] Multiple factors, including the activation of oncogenes, deactivation of tumor suppressors and other hereditary and epigenetic alterations, are involved in the initiation and progression of breast cancer. [8] [9] [10] However, details of the underlying mechanisms regulating breast cancer progression
are not yet fully understood. Thus, a comprehensive understanding of the molecular mechanisms underlying breast cancer pathogenesis is crucial for the identification of novel targets for precision therapy. MicroRNAs (miRNAs) are a group of evolutionarily conserved, noncoding and short RNA molecules 19-24 nucleotides long.
11 miRNAs act as gene expression regulators by imperfect or near-perfect base pairing with the 3′-UTRs of their target mRNAs, thereby resulting in translation suppression and/or mRNA degradation. 12 Multiple lines of evidence have demonstrated that nearly all cellular physiological and pathological processes are closely regulated by miRNAs including carcinogenesis and cancer progression. [13] [14] [15] The aberrant expression of miRNAs is a common and important feature of breast cancer, and their dysregulation participates in the malignant phenotypes of breast cancer by acting as oncogenes or tumor suppressors. [16] [17] [18] Therefore, silencing of oncogenic miRNAs and restoring the expression of tumorsuppressing miRNAs might be a promising therapeutic method for patients with breast cancer. Long noncoding RNAs (lncRNAs) are another group of noncoding RNA transcripts that are implicated in the regulation of various pathological processes, by performing important functions in the malignant progression of human cancers. 19 It is well-known that lncRNAs are able to serve as competing endogenous RNAs (ceRNAs) to modulate the expression of genes by sponging miRNAs, thus titrating available miRNAs and contributing to tumorigenesis, including breast carcinogenesis. [20] [21] [22] Accordingly, further exploration of the specific functions of lncRNAs in breast cancer is likely to provide effective targets for the development of therapies. Abnormal expression of miR-876-5p (miR-876) contributes to the aggressiveness of multiple types of human cancer, including osteosarcoma, 23 hepatocellular carcinoma, 24 lung cancer, 25 and head and neck squamous cell carcinoma. 26 However, whether miR-876 is aberrantly expressed in breast cancer and its mechanisms of action
have not yet been investigated. In this article, we provided experimental evidence that miR-876 is sponged by LINC00707 and can restrain breast cancer progression through metadherin (MTDH) downregulation.
Materials and methods

Ethics statement
The Ethics Committee of The Fourth People's Hospital of Jinan approved the study protocol, and written informed consent was provided by all individual participants prior to surgical resection. All the experimental procedures were in accordance with the Declaration of Helsinki.
Tissues and cell lines
In total, 53 pairs of breast cancer samples and adjacent normal tissues were collected from breast cancer patients at The Fourth People's Hospital of Jinan who had not been treated with any preoperative therapies, such as radiotherapy or chemotherapy. The tissue samples were snap-frozen in liquid nitrogen after surgical excision and stored at −80°C until total RNA and protein isolation.
The four breast cancer cell lines, MCF-7, MDA-MB-231, BT-474 and SKBR3, and human breast epithelial cell line MCF-10A were purchased from the Chinese Academy of Sciences (Shanghai, China). All the cell lines were kept at 37°C in a humidified chamber with 5% CO 2 and were grown in DMEM containing 10% FBS and 1% penicillin-streptomycin mixture (all from Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA).
Transfection
The miR-876 agomir (agomir-876), negative control agomir (agomir-NC), miR-876 antagomir (antagomir-876) and antagomir-NC were acquired from Shanghai GenePharma Co., Ltd. (Shanghai, China). The small interfering RNA (siRNA) targeting LINC00707 (si-LINC00707) and the negative control siRNA (si-NC) were chemically synthesized by Guangzhou RiboBio Co. Ltd. (Guangzhou, China). The MTDH sequence lacking its 3′-UTR was produced by Guangzhou RiboBio Co. Ltd., inserted into the pcDNA3.1 plasmid, and the resulting plasmid was named pcDNA3.1-MTDH (pc-MTDH). Cells were seeded in 6-well plates 24 hrs prior to transfection. Transient transfection was performed using Lipofectamine ® 2000 (Thermo Fisher Scientific, Inc.), as per the manufacturer's protocol.
RNA isolation and RT-qPCR
Total RNA was isolated with TRIzol ® Reagent (Thermo Fisher Scientific, Inc.), and the concentration and quality were determined using a Nanodrop ® ND-1000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc). miR-876 expression was determined by 
Flow cytometric analysis of apoptosis
After 48 hrs culture, the transfected cells were harvested, washed three times with ice-cold PBS and analyzed for cell apoptosis using the Annexin V-FITC Apoptosis Detection Kit (BioLegend, San Diego, CA, USA). In particular, the transfected cells were resuspended in 100 µL binding buffer supplemented with 5 µL Annexin V-FITC and 5 µL propidium iodide. Following 30-min incubation at room temperature in the dark, the prevalence of apoptosis was determined using a flow cytometer (FACScan, BD Biosciences, Heidelberg, Germany). CellQuest software (BD Biosciences, Heidelberg, Germany) was employed to analyze the data.
Transwell migration and invasion assays
Migration and invasion were examined using a 24-well 
A luciferase reporter assay
The 3′-UTR fragments of MTDH containing the wild-type (WT) or mutant (MUT) miR-876-binding site were amplified by Shanghai GenePharma Co. Ltd. and cloned into the psiCHECK2 vector (Promega Corporation, Madison, WI, USA). These luciferase reporter plasmids were designated as MTDH-WT and MTDH-MUT, respectively. LINC00707-WT and LINC00707-MUT reporter plasmids were also produced by Shanghai GenePharma Co. Ltd. Cells were seeded in 24-well plates and co-transfected with the luciferase reporter plasmids and agomir-876 or agomir-NC by means of Lipofectamine ® 2000. Finally, the cells were collected, and luciferase activity was detected using the Dual Luciferase Reporter Assay (Promega Corporation, Madison, WI, USA). Firefly luciferase activity was normalized to Renilla luciferase activity.
Western blotting
Cell lysates were prepared using radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China). The total protein concentration was measured using the BCA Protein Assay kit (Pierce; Thermo Fisher Scientific, Inc. 
Statistical analysis
Each experiment was repeated at least three times. All data are expressed as mean ± SD and were analyzed in the SPSS software, version 16 (SPSS, Inc., Chicago, IL, USA). Pearson's χ 2 test was conducted to determine the association between miR-876 and clinical characteristics among patients with breast cancer. Correlation between miR-876 and MTDH as well as LINC00707 expression in the same breast cancer tissues was examined via Spearman's correlation analysis. The KaplanMeier method along with the log-rank test was applied to assess the prognostic value of miR-876 in patients with breast cancer. P<0.05 was assumed to indicate a statistically significant difference.
Results
Expression profile of miR-876 in breast cancer and its associations with clinical factors
To obtain an overview of the expression profile of miR-876, we first measured its expression in 53 pairs of breast cancer samples and adjacent normal tissues. An obvious decrease in miR-876 expression was identified in breast cancer tissue samples compared with that in adjacent normal tissue samples ( Figure 1A , P<0.05). Similarly, the expression of miR-876 was significantly lower in MCF-7, MDA-MB-231, BT-474 and SKBR3 cell lines than in human breast epithelial cell line MCF-10A, especially in the MCF-7 and MDA-MB-231 cell lines ( Figure 1B , P<0.05). Therefore, the two cell lines were chosen for further experiments. We next investigated whether miR-876 expression in breast cancer tissues correlated with clinical factors. All breast cancer patients were classified into either low-or high-miR-876 expression groups, based on the median miR-876 expression level in breast cancer tissues. There was no significant correlation between miR-876 expression and age (P=0.158), or tumor size (P=0.412) of patients with breast cancer. However, a significant correlation was observed between decreased miR-876 expression and lymphatic invasion metastasis (P=0.002), TNM stage (P=0.034) and differentiation grade (P=0.029; Table 1 ). We also analyzed the overall survival rate of breast cancer patients with low or high miR-876 expression levels. The results revealed that patients with breast cancer and low miR-876 expression had shorter overall survival than patients with relatively high levels of miR-876 expression ( Figure 1C , P=0.012). These observations suggested that aberrant expression of miR-876 may be closely related to the initiation and progression of breast cancer.
miR-876 upregulation inhibits breast cancer cell growth and metastasis in vitro
To manipulate the expression of miR-876 in breast cancer cells, synthetic agomir-876 was introduced into MCF-7 and MDA-MB-231 cells. RT-qPCR analysis clearly confirmed that miR-876 was effectively upregulated in MCF-7 and MDA-MB-231 cells after agomir-876 transfection (Figure 2A , P<0.05). A CCK-8 assay for cellular proliferation showed that ectopic miR-876 expression notably decreased the proliferation of MCF-7 and MDA-MB-231 cells ( Figure 2B , P<0.05). The influence of miR-876 overexpression on breast cancer cell apoptosis was next examined via flow cytometric analysis. As presented in Figure 2C , the proportion of apoptotic cells increased when miR-876 was overexpressed in MCF-7 and MDA-MB-231 cells (P<0.05). Furthermore, Transwell migration and invasion assays indicated that agomir-876 transfection led to obvious reductions in MCF-7 and MDA-MB -231 cell migration and invasion ( Figure 2D and E, P<0.05). These results collectively meant that miR-876 functions as a tumor-suppressing miRNA in breast cancer.
MTDH is a direct target of miR-876 in breast cancer cells
As for the mechanism, miRNAs are known to regulate the expression of their targets. 12 Accordingly, identifying the direct target gene of miR-876 in breast cancer cells was essential for understanding its role in the aggressiveness of breast cancer. Bioinformatics analysis predicted that the 3′-UTR of MTDH mRNA contains a complementary binding site for miR-876 ( Figure 3A ). The luciferase reporter assay was conducted to determine whether MTDH mRNAwas a direct target of miR-876 in breast cancer. The results revealed that transfection of agomir-876 significantly reduced the luciferase activity of MTDH-WT in MCF-7 and MDA-MB-231 cells (P<0.05), whereas cotransfection of agomir-876 and MTDH-MUT did not affect luciferase activity ( Figure 3B and C). We next evaluated the potential association between miR-876 and MTDH in breast cancer. RT-qPCR analysis indicated that MTDH mRNA expression was higher in breast cancer tissue samples than in adjacent normal tissues ( Figure 3D 
Restoring MTDH expression reduces miR-876-mediated inhibition of breast cancer cell growth and metastasis in vitro
To test whether MTDH is involved in miR-876's tumorsuppressive effects in breast cancer, we restored MTDH expression in miR-876-overexpressing MCF-7 and MDA-MB-231 cells by cotransfection with the MTDH overexpression plasmid pc-MTDH. Unsurprisingly, upregulation of miR-876 noticeably decreased MTDH protein expression in MCF-7 LncRNA LINC00707 acts as a sponge for miR-876 in breast cancer cells
It is well-known that lncRNA can act as a molecular sponge binding miRNAs and thereby titrating free miRNA. 19 Thus, we hypothesized that miR-876 is sponged by some lncRNA, resulting in the restriction of breast cancer progression. To test this hypothesis, bioinformatics analysis was performed and two potential miR-876-binding sites in LINC00707 were identified ( Figure 5A ). The luciferase reporter assay was then carried out to confirm that miR-876 is a downstream target of LINC00707 in breast cancer cells. It was observed that miR-876 overexpression significantly suppressed the luciferase activity of LINC00707-WT (both 1 and 2) in MCF-7 and MDA-MB-231 cells ( Figure 5B ; P<0.05). However, transfection with agomir-876 failed to affect the luciferase activity of LINC00707-MUT (both 1 and 2). RT-qPCR analysis confirmed that LINC00707 expression was higher in breast cancer tissue samples than in adjacent normal tissue samples ( Figure 5C, P<0.05) . Importantly, LINC00707 expression negatively correlated with miR-876 expression in the same breast cancer tissue ( Figure 5D ; R 
LINC00707 knockdown inhibits the proliferation, migration and invasiveness and induces the apoptosis of breast cancer cells
To explore the specific roles of LINC00707 in breast cancer, si-LINC00707 was transfected to silence LINC00707 expression in MCF-7 and MDA-MB-231 cells. si-NC acted as the control for si-LINC00707. Predictably, the LINC00707 knockdown significantly decreased the proliferation of MCF-7 and MDA-MB-231 cells ( Figure 6A, P<0.05 ). In addition, LINC00707-depleted MCF-7 and MDA-MB-231 cells showed significantly more apoptosis ( Figure 6B, P<0.05) . Furthermore, Transwell migration and invasion assays indicated that the number of cells that migrated ( Figure 6C , P<0.05) and invaded ( Figure 6D , P<0.05) was lower in the si-LINC 00707 group than in the si-NC group. These findings confirmed that LINC00707 has tumor-promoting effects on the growth and metastasis of breast cancer in vitro. However, cotransfection with antagomir-876 abrogated these effects of LINC00707 silencing. In summary, these results suggested that LINC00707 is implicated in the regulation of breast cancer progression by regulating miR-876 activity.
MiR-876 upregulation decreases tumor growth of breast cancer cells in vivo
Tumor xenograft experiments were conducted to examine the function of miR-876 overexpression in breast cancer tumor growth in vivo. The volumes ( Figure 8A and B, P<0.05) and weights ( Figure 8C , P<0.05) of tumor xenografts were both smaller in the agomir-876 group than in the agomir-NC group. In addition, RT-qPCR analysis showed that miR-876 expression in tumor xenografts from the agomir-876 group was higher than that in the agomir-NC group ( Figure 8D, P<0.05) . Then, we measured the MTDH protein levels in the formed tumor xenografts. MTDH protein expression was also downregulated in vivo after miR-876 upregulation ( Figure 8E, P<0.05) . These results suggested that miR-876 exerts an inhibitory action on the tumor growth of breast cancer cells in vivo.
Discussion
In recent years, aberrant miRNA expression has been identified in breast cancer, which has important roles in the progression of malignancy. 28 miRNAs can act as tumor suppressors or oncogenic molecules depending on the biological functions of their targets. 29 Therefore, exploring the functions of cancer-specific miRNAs in breast cancer and their mechanisms of action is needed to identify effective targets for anticancer therapy. In this study, for the first time, we measured the expression of miR-876 in breast cancer and evaluated its clinical value. In addition, the detailed roles of miR-876 in the progression of breast cancer were explored using a series of experiments. Notably, another aim of this study was to determine the mechanisms underlying the activity of miR-876 in breast cancer progression, which might be helpful for identifying promising targets for novel treatments. miR-876 is downregulated in osteosarcoma, and its downregulation positively correlates with an advanced clinical stage and poor differentiation status. 23 Patients with osteosarcomas that have low miR-876 expression exhibit worse overall survival than patients with high miR-876 expression. 23 miR-876 is also expressed at low levels in hepatocellular carcinoma, 24 lung cancer, 25 and head and neck squamous cell carcinoma. 26 Nevertheless, to date, few studies have focused on the expression profile of miR-876 in breast cancer. Here, we found that miR-876 expression is low in breast cancer tissues and cell lines. Low miR-876 expression correlated with lymphatic invasion metastasis, TNM stage and differentiation grade. More importantly, patients with breast cancer containing low levels of miR-876 showed lower overall survival than patients with high levels of miR-876 expression. These observations suggest that miR-876 might be an effective diagnostic and prognostic biomarker for patients with breast cancer.
miR-876 has tumor-suppressive roles in the carcinogenesis and cancer progression. For instance, miR-876 upregulation restricts osteosarcomas cell proliferation, migration and invasion in vitro and hinders tumor growth in vivo. 23 Ectopic miR-876 expression suppresses cell metastasis in head and neck squamous cell carcinoma both in vitro and in vivo. 26 Furthermore, miR-876 has been validated as a tumor-suppressing miRNA in hepatocellular carcinoma 24 and lung cancer. 25 However, whether miR-876 is involved in breast cancer progression has remained unknown until now. In this study, restoring miR-876 expression decreased the proliferation, migration and invasion of breast cancer cells in vitro and promoted cell apoptosis. In addition, miR-876 overexpression dramatically delayed the growth of breast cancer-derived tumors in vivo. Accordingly, miR-876 has potential as an effective target for breast cancer therapy.
Multiple genes, including c-Met in osteosarcoma, 23 BCL6
corepressor-like 1, 24 DNA (cytosine-5)-methyltransferase 3A 30 in hepatocellular carcinoma and bone morphogenetic protein 4 in lung cancer, 25 have been identified as direct target genes of miR-876. Currently, the lncRNA-miRNA-mRNA axis is the most typical regulatory mechanism for lncRNA. Here, MTDH mRNA was identified as a direct target of miR-876 in breast cancer cells, with LINC00707 acting as a ceRNA for miR-876 to regulate MTDH expression. MTDH is upregulated in breast cancer and its overexpression is related to nuclear grade, negative estrogen receptor and progesterone receptor expression, disease-free survival, distant-metastasisfree survival and overall survival. 31 Multivariate analysis identified MTDH as an independent biomarker of poor disease-free survival and distant metastasis-free survival rates. 31 MTDH functions in many biological processes closely related to breast cancer formation and progression. [32] [33] [34] [35] 
Conclusion
We proved that miR-876 is downregulated in breast cancer tissues and cell lines, and that its decreased expression is associated with poor prognosis among patients with breast cancer. This study also uncovered the role of the LINC00707-miR-876-MTDH pathway in the malignant progression of breast cancer and provided novel targets for the management of breast cancer. However, we did not explore the effect of miR-873 on the metastasis of breast cancer in vivo. It is a limitation of our study, and we will resolve it in our future investigation.
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